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Abstract
Background: The 14-3-3 family is comprised of highly conserved proteins that are functionally important in the
maintenance of homeostasis. Their involvement with the cell cycle, their association with proto-oncogenes and oncogenes,
and their abnormal expression in various tumors has linked this family of proteins to the etiology of human cancer.
Mounting evidence now indicates that 14-3-3s is a cancer suppressor gene but the roles of the other 14-3-3 isoforms and
their interactions in tumorigenesis have not yet been elucidated. In our current study, we examined the expression of 14-3-
3b, c, e, f, g and t in a large series of vulvar squamous cell carcinomas to evaluate any clinical significance.
Methods: Tumor biopsies from 298 vulvar carcinomas were examined by immunohistochemistry for the expression of 14-3-
3b, c, e, f, g and t. Statistical analyses were employed to validate any associations between the expression of any 14-3-3
isoform and clinicopathologic variables for this disease.
Results: High cytoplasmic levels of 14-3-3b, c, f, e and g were observed in 79%, 58%, 50%, 86% and 54% of the vulvar
carcinomas analyzed, respectively, whereas a low nuclear expression of 14-3-3t was present in 80% of these cases. The
elevated cytoplasmic expression of 14-3-3b, c, e, f and g was further found to be associated with advanced disease and
aggressive features of these cancers. The overexpression of cytoplasmic 14-3-3b and e significantly correlated with a poor
disease-specific survival by univariate analysis (P=0.007 and P=0.04, respectively). The independent prognostic significance
of these factors was confirmed by multivariate analysis (P=0.007 and P=0.009, respectively).
Conclusions: We reveal for the first time that the 14-3-3b, c, e, f, g and t isoforms may be involved in the progression of
vulvar carcinomas. Furthermore, our analyses show that high cytoplasmic levels of 14-3-3b and e independently correlate
with poor disease-specific survival.
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Introduction
Vulvar squamous cell carcinoma accounts for 3–5% of all
gynecological carcinomas [1] and is subcategorized into human
papillomavirus (HPV)-independent type and HPV-associated type
[2]. The HPV-independent type comprises ,80% of cases and
presents mainly in older patients, whereas the HPV-associated type
accounts for ,20% of these patients and occurs at a comparatively
younger age [3]. However, an increasing incidence of these lesions
among younger women has been reported recently [4,5]. Surgery
remains the standard treatment for vulvar squamous cell carcinoma
and patients with advanced stage diseases are subjected to more
extensive and radical surgical interventions, which incurs a higher
risk of post-operative complications [6]. Individualized therapy,
with the prospect of maximizing the impact of a particular
treatment approach, concomitant with fewer complications, is
therefore highly desirable in these cases. The identification of new
biomarkersofthe progressionofvulvarcarcinomaswillgreatlyassist
with the development of such therapies. In this regard, the 14-3-3
protein family warrants particular attention.
The highly conserved 14-3-3 protein family is present in a broad
range of organisms [7]. The 14-3-3 proteins are specific
phosphoserine/threonine-binding proteins and in humans, seven
isoforms (b, c, e, f, g, s and t) have been identified [8]. Their
remarkable level of conservation indicates a vital role in cellular
physiology [7] and indeed the 14-3-3 proteins interact with a wide
variety of cellular molecules via consensus motifs and thereby
regulate their activities through different mechanisms [9]. The
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enzymes, cytoskeletal proteins, signaling molecules, apoptosis
factors and tumor suppressors [8]. In addition, interactions with
multiple proto-oncogene and oncogene products [7] and partic-
ipation in mitogenic signaling pathways including CDC25 have
raised speculations over the roles of the 14-3-3 proteins in the
development and progression of malignancy, and also their
potential as therapeutic targets [9]. CDC25 phosphatases, which
are principal regulators of the entry into mitosis via the activation
of CDK1/cyclin B, are themselves regulated spatially and
temporally by 14-3-3 in mitogenic signaling pathways [10].
The abnormal expression of 14-3-3 proteins has been reported
in various types of carcinoma, including lung [11], gastric [12] and
oral carcinoma [13]. Deregulation of some of the 14-3-3 isoforms
has also been shown to contribute to tumorigenesis by enhancing
tumor aggressiveness [7,9]. To our knowledge, with the exception
of 14-3-3s, the profile of the 14-3-3 isoforms in vulvar cancers has
not been previously reported. We thus investigated the expression
profile of these other 14-3-3 isoforms in a large series of vulvar
squamous cell carcinomas to evaluate their potential as prognostic
indicators of this disease.
Methods
Patient materials
A retrospective study was performed on a cohort of 298 patients
who had been diagnosed with vulvar squamous cell carcinoma and
had undergone a resection at The Norwegian Radium Hospital
between 1977 and 2006. The median age at diagnosis was 74
years (range, 35–96 years). Nine of these patients had received
other treatments prior to surgery, including six cases that were
treated by radiotherapy and three cases that received a combined
radiotherapy/chemotherapy intervention. Radical surgery (a total
vulvectomy plus a bilateral inguinal lymphadenectomy) was
performed in 181 (61%) of these cases and the remaining 117
(39%) patients received non-radical surgery. Postoperative therapy
was administered to 70 patients including irradiation in 63 (21%)
cases, chemotherapy in three (1%) cases and irradiation/
chemotherapy in four (1%) cases. One hundred and twenty-two
(41%) of the patients in this cohort died as a result of their vulvar
cancer. All patients were followed up from the time of their
confirmed diagnosis until death or 1 September, 2009. The
median follow-up time was 151 months (range, 43 to 378 months).
The tumors were all staged based on the new International
Federation of Gynecology and the Obstetrics (FIGO) classification
from 2009 [14]. The Regional Committee for Medical Research
Ethics South of Norway (S-06012), The Social and Health
Directorate (04/2639 and 06/1478) and The Data Inspectorate
(04/01043) approved the current study protocol.
All histological specimens were reviewed by J.M.N. (a co-
author) without access to any clinical information on the patients
and tumor classifications adhered strictly to the World Health
Organization recommendations [15]. Two hundred and eighty
(94%) tumors were classified as keratinizing/non-keratinizing, 14
(5%) as basaloid and four (1%) as veruccous. Control samples of 10
normal vulva tissues from patients with benign gynecological
diseases were also collected following surgery. Results from our
previous studies on 14-3-3s and CDC25s expression in this same
cohort of vulvar carcinomas [16,17] were co-analyzed with those
of the current study.
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections were processed for
immunohistochemistry using the Dako EnVision
TM Flex+ System
(K8012; Dako, Glostrup, Denmark) and the Dako Autostainer.
Deparaffinization and the unmasking of epitopes were performed
using PT-Link (Dako) and EnVision
TM Flex target retrieval
solution at a low pH. To block endogenous peroxidase activity, the
sections were treated with 0.03% hydrogen peroxide (H2O2) for
5 min. The sections were then incubated for 30 min with
polyclonal rabbit antisera raised against 14-3-3b (AHP1044,
1:1000), 14-3-3c (AHP1047, 1:2000), 14-3-3f (AHP1052,
1:2000), 14-3-3e (AHP1048, 1:1000), 14-3-3g (AHP1046,
1:3000) or 14-3-3t (AHP1051, 1:1000), all of which were
purchased from AbD Serotec (Oxford, UK). The primary
antibodies against the 14-3-3b and f isoforms showed low cross-
reactivity with 14-3-3f and b, respectively, whereas all other 14-3-
3 primary antibodies showed a high degree of specificity [18].
Following the antibody treatments, the slides were incubated
with EnVision
TM Flex+ rabbit linker (15 min) and EnVision
TM
Flex/HRP enzyme (30 min). The tissues were subsequently
stained for 10 minutes with 393-diaminobenzidine tetrahy-
drochloride (DAB) and then counterstained with hematoxylin.
The samples were then dehydrated and mounted in Diatex. All of
the sample series included appropriate positive controls, which
included cervical cancer (14-3-3b), ovarian cancer (14-3-3e and f),
colon cancer (14-3-3g and c) and prostate cancer (14-3-3t)
sections. As negative controls, the polyclonal rabbit antisera were
replaced with normal rabbit serum at the equivalent dilution.
A semi-quantitative scale was used to score the immunohisto-
chemical signals detected in the cancer cells on each section both
in the cytoplasm and the nucleus. The scores (range, 0 to 9) were
individually produced by multiplying the value for the intensity of
the signal (absent, 0; weak, 1; moderate, 2; strong, 3) by the extent
of the immunoreactivity (i.e. the percentage of positive cancer
cells: absent, 0; ,10%, 1; 10–50%, 2; .50%, 3). The cutoff value
for the immunoreactivity of each 14-3-3 isoform in the cytoplasm
or nucleus was chosen based on the individual staining pattern for
each in the normal vulvar epithelium. High cytoplasmic
immunostaining for the different isoforms was classified as follows:
score .1 for 14-3-3b and e, score .3 for 14-3-3c, f and g and
score .0 for 14-3-3t. High nuclear immunostaining for the
isoforms was assigned as follows: score .0 for 14-3-3b, c and g
and score $6 for 14-3-3f, e and t. The immunostaining results
were evaluated independently by two observers (Z.W. and R.H.)
with no prior knowledge of the patient outcomes. All discordant
scores were reviewed until a final agreement was obtained.
Statistical analyses
The Pearson’s chi-square (x
2) test was used to find associations
between the 14-3-3 isoform expression patterns and the clinico-
pathologic variables. The disease-specific survival analysis was
processed using the Kaplan and Meier estimation and log-rank
test. A Cox proportional hazards regression model was used for
further analyses of the univariate and multivariate evaluations of
survival rates. In the multivariate analysis, a backward stepwise
regression was executed among variables that were eligible with a
P#0.05 in the univariate analysis. All analyses were processed
using the SPSS 16.0 statistical software package (SPSS, Chicago,
IL). Statistical significance was considered for P#0.05.
Results
14-3-3 protein expression
In 10 cases of normal vulvar squamous epithelium the
cytoplasmic staining was observed for 14-3-3b (score #3), 14-3-
3c (score 3), 14-3-3f (score 3) and 14-3-3e (score #3) in the basal,
parabasal, middle and top layers, whereas cytoplasmic staining for
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layers. Nuclear staining for 14-3-3f (score $6), 14-3-3e (score 6)
and 14-3-3t (score $6) was detected as a constant distribution
from the basal to top layers (Figures 1A–F). The subcellular
immunostaining assessment of each 14-3-3 isoform in the vulvar
carcinoma series under study is summarized in Table S1. In the
cytoplasm, a high expression of 14-3-3b (score .1), 14-3-3c (score
.3), 14-3-3f (score .3), 14-3-3e (score .1) and 14-3-3g (score
.3) was observed in 79% (236/298), 58% (172/298), 50% (150/
298), 86% (256/298) and 54% (160/298) of the patients,
respectively (Figures 1G-K). In the nucleus, a high expression of
14-3-3b, c and g (all score .0) was observed in 8% (24/298), 15%
(47/298) and 1% (3/298) of the cases, respectively. A low signal for
14-3-3f and e (both score ,6) in the nucleus was found in 97%
(289/298) and 98% (291/298) of the cases, respectively. Low
nuclear expression of 14-3-3t (score ,6) was also found in 80%
(239/298) of the patients (Figure 1L).
Association of the 14-3-3 isoform immunostaining
profiles with the clinicopathological parameters and
CDC25 isoform status
The expression patterns of all of the 14-3-3 isoforms (nuclear
staining for t and cytoplasmic expression for all others) were found
to correlate with the tumor diameter in the vulvar squamous cell
carcinoma patient subjects. The expression of 14-3-3b, c, f, e and
g correlated with the depth of tumor invasion, whereas the
expression of 14-3-3c and f correlated with the FIGO substage of
these cancers. Moreover, the expression of 14-3-3c correlated with
the advancement of lymph node metastasis and the expression of
14-3-3g correlated with the tumor differentiation. None of the 14-
3-3 isoforms showed any association with the patient’s age or with
vessel infiltration (Table S2). The expression patterns of the 14-3-
3b, c, f, e and g isoforms in the nucleus were also not found to
significantly correlate with any of the clinicopathological param-
eters tested for the patient cohort. The expression of all of the 14-
3-3 isoforms (in the nucleus for t and in the cytoplasm for all
others) correlated with that of phospho-CDC25C (Ser216).
Further, the expression of 14-3-3c, e, f and g correlated with
that of CDC25C and the expression of 14-3-3b, e, f, g and t with
that of CDC25A. The expression of 14-3-3c correlated with that
of CDC25B (Table S3). Moreover, the expression of 14-3-3b, c, f,
e and g correlated significantly with all other 14-3-3 isoforms with
the exception of 14-3-3t (Table S3).
By univariate analysis, the high cytoplasmic expression of 14-3-
3b and e was found to be associated with a poor disease-specific
survival outcome (Figure 2). By multivariate analysis, FIGO,
lymph node metastasis, age, vessel infiltration and the cytoplasmic
expression of 14-3-3b and e were found to retain their
independent prognostic significance for vulvar squamous cell
carcinoma (Table 1).
Discussion
Compared with the expression of 14-3-3 isoforms in normal
vulvar tissues, the higher cytoplasmic expression of 14-3-3b, c, f, e
and g, the higher nuclear expression of 14-3-3b, c and g, and the
lower nuclear expression of 14-3-3f and e were observed in our
current analyses of a vulvar carcinoma patient sample series. Our
results indicated that the expression of 14-3-3t is restricted to the
nucleus and is downregulated in 80% of the vulvar cancer cases in
our cohort when compared with normal tissue. The elevated
cytoplasmic expression of 14-3-3b, c, f, e and g was found to be
associated with advanced disease and aggressive tumor character-
istics, including a high FIGO substage, the presence of lymph node
metastases, large tumor diameters, deeper invasiveness and/or a
low histologic grade. Furthermore, our current findings revealed
that the high cytoplasmic levels of 14-3-3b and e significantly
correlated with a poor disease-specific survival outcome for vulvar
squamous cell carcinoma by both univariate and multivariate
analysis.
The expression of 14-3-3b and e and its association with patient
outcomes have not been previously investigated for any human
cancer. In our present study, we show that high cytoplasmic levels
of both 14-3-3b and e significantly correlate with a shorter survival
time for patients with vulvar carcinoma. Pathogenic roles of 14-3-
3b and e have been previously reported in several studies. The
exogenous expression of 14-3-3b increased the proliferation of
NIH3T3 cells, their colony formation in soft agar, and tumor
formation in nude mouse xenograft experiments [7]. In hepatoma
cells, the downregulation of 14-3-3b by antisense 14-3-3b RNA
was found to suppress tumor cell growth both in vitro and in vivo
Figure 1. The expression of 14-3-3 proteins in the vulvar
squamous epithelium. Representative samples stained using immu-
nohistochemistry are shown. The expression of the 14-3-3 proteins
(b, c, f, e, g and t) in normal vulvar squamous epithelium (A–F). The
increased cytoplasmic expression of 14-3-3b, c, f, e and g (G–K) and the
reduced nuclear expression of 14-3-3t (L) in vulvar carcinomas.
doi:10.1371/journal.pone.0024843.g001
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decrease in VEGF production, inhibit angiogenesis, increase
apoptosis and suppress tumor size [20]. Furthermore, the
upregulation of 14-3-3e has been demonstrated to play an
important role in the development of human renal carcinoma
[21] and meningioma [22]. In our current experiments, elevated
14-3-3b and e significantly correlated with a large tumor diameter
and enhanced invasiveness. Cao et al. [23] and Liu et al. [22] have
reported in earlier studies of human astrocytomas and meningi-
omas, respectively, that the expression of 14-3-3b is markedly
increased concomitantly with an increase in the pathological
grade. A further study of larynx carcinomas has found that the
protein levels of 14-3-3e are significantly lower in stage III or IV
tumors compared with stage I or II lesions [24]. Taken together,
these findings suggest that 14-3-3b and e are involved in the
progression of vulvar carcinomas and may predictive markers of
the survival outcomes in affected patients. Further studies will be
needed to confirm the potential of 14-3-3b and e as prognostic
markers of cancer in a clinical setting.
Our present results show a high expression of the 14-3-3c, f and
g isoforms in the cytoplasm of a high proportion of vulvar
carcinoma samples and a significantly correlation between this
expression profile and malignancy in these cancers, including a
large tumor diameter and increased invasiveness. 14-3-3c and f
expression also significantly correlated with a high FIGO substage,
and the 14-3-3c levels further correlated with presence of lymph
node metastases and that 14-3-3g correlated with more poorly
differentiated tumor cells. In agreement with our current findings,
several earlier studies have reported the upregulation of 14-3-3c
and f in different tumor types. Elevated 14-3-3c expression has
been described in lung cancer [25,26] and in some papillomavirus-
induced carcinomas [27]. A high level of 14-3-3f has also been
found in oral squamous cell carcinoma [13], stomach cancer [12],
breast cancer [28] and meningioma [22]. Few studies have
investigated the upregulation of 14-3-3g in cancer. However, Cao
et al. [23] have previously demonstrated a high level of 14-3-3g in
human astrocytomas. In line with our current findings also, 14-3-
3g expression has been shown to be markedly augmented in
parallel with an increased pathological grade in human astrocy-
tomas [23]. We speculate therefore that the increased expression
of the 14-3-3c, f and g isoforms may be involved in the
carcinogenesis of different tumors, including vulvar carcinoma.
This speculation is strengthened by the findings of previous reports
showing that exogenous 14-3-3c leads to polyploidization in H322
lung cancer cells [25], that the overexpression of 14-3-3c in a lung
Figure 2. Survival curves using the Kaplan-Meier method. The
Kaplan-Meier curve of disease-specific survival in relation to the
cytoplasmic expression of 14-3-3b and e. The p-value for 14-3-3b differs
slightly from that in Table 1 based on the use of the log-rank test in
Figure 2 as opposed to the use of the Cox-regression analysis in Table 1.
doi:10.1371/journal.pone.0024843.g002
Table 1. Relative risk (RR) of dying from vulvar cancer.
Variables Univariate analysis Multivariate analysis
RR 95% CI
a P RR 95% CI
a P
FIGO 1.51 1.38–1.65 ,0.001 1.29 1.12–1.49 0.001
Lymph node metastasis 2.45 1.90–3.14 ,0.001 1.84 1.33–2.53 ,0.001
Age 1.62 1.24–2.12 ,0.001 1.68 1.20–2.34 0.002
Infiltration of vessel 2.47 1.69–3.61 ,0.001 1.82 1.17–2.83 0.008
Tumor diameter 1.75 1.38–2.21 ,0.001 - - -
14-3-3b cytoplasmic staining
b 2.00 1.19–3.32 0.009 2.42 1.27–4.60 0.007
14-3-3e cytoplasmic staining
b 1.96 1.02–3.74 0.04 3.40 1.36–8.46 0.009
a95% confidence interval.
bCytoplasma: low #1 and high .1.
doi:10.1371/journal.pone.0024843.t001
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overexpression of 14-3-3f induces the proliferation of breast
cancer cells [28]. Furthermore, our current results suggest that
elevated 14-3-3c, f and g expression play an important role in the
progression of vulvar carcinomas, despite their limited value as
predictors of survival outcomes.
The low expression of 14-3-3t in the nucleus was identified in 80%
of vulvar cancer cases in our present patient cohort when compared to
its high levels in normal vulvar tissues. In addition, the low nuclear
expression of this isoform significantly correlated with larger tumor
diameters butnot with disease-specific survival. Our results thus suggest
that the downregulation of 14-3-3t may be involved in the
tumorigenesis of vulvar cancer. In contrast, Martin et al. [29] have
reported that the increased expression of 14-3-3t enhances the growth
rate of mammary carcinoma cells by promoting cell adhesion to
tenascin-C, an extracellular matrix protein. These differences in the
effects of the 14-3-3t protein may indicate tumor type-specific roles.
Our results additionally show that the high cytoplasmic
expression of 14-3-3b, c, e, f and g significantly correlates with
all other 14-3-3 isoforms with the exception of 14-3-3t. This
suggests that both homo- and hetero-dimer complexes of 14-3-3
isoforms are formed in vulvar carcinomas. Little is known about
the interactions between 14-3-3 isoforms in the cell but these
proteins have been found to form thermodynamically stable
homo- or hetero-dimers [30]. For example, 14-3-3c forms
homodimers as well as heterodimers with 14-3-3e. In turn, 14-3-
3e may preferentially form heterodimers rather than homodimers
with another family member such as the b, c, f and g isoforms
[30]. By forming dimers, 14-3-3 proteins can adopt a wide variety
of tertiary structures to bind different protein ligands, which
accounts for the multiple roles of these proteins in the regulation of
a wide variety of cellular processes [30].
We observed a significant correlation between cytoplasmic 14-3-
3b,e,f and gandnuclearCDC25A,aswellasbetween cytoplasmic
14-3-3c and nuclear CDC25B. Because 14-3-3 and CDC25
isoforms localize in different subcellular regions, these significant
correlations indicate that indirect connections occur between these
isoforms. The cytoplasmic overexpression of CDC25C and
phospho-CDC25C (Ser216) was found in our analysis to correlate
with a high cytoplasmic expression of 14-3-3c, e and g. Previously,
a number of studies reported that the phosphorylation of Ser216 on
CDC25Cwasrequired for itsbindingto 14-3-3[31-33]. Telleset al.
[31] have further reported that the unique secondary structure of
14-3-3e, as indicated by the Phe135 residue, and 14-3-3c, due to an
E94-K142 salt bridge, are required to form the 14-3-3e/c-
CDC25C heterodimer, which inhibits CDC25C function. We
suggest from our present data that in vulvar carcinomas, 14-3-3c
and e are the two most likely isoforms to form complexes with
phospho-CDC25C (Ser216) and to thereby regulate CDC25C
function. This complexhasbeen found to sequester CDC25C inthe
cytoplasm, which prevents its binding to CDK1/cyclin B [10].
Hence, this complex serves to negatively regulate the cell cycle.
Interestingly, our previous analysis of the same cohort of vulvar
carcinoma cases revealed that 70% of the tumors displayed a high
nuclear expression of phospho-CDC25C (Ser216) [17]. This
phenomenon may be explained by the relatively lower levels of
14-3-3c and e compared with those of phospho-CDC25C (Ser216)
in these lesions. Once the binding capacity of 14-3-3 and phospho-
CDC25C (Ser216) is saturated, unbound CDC25C (Ser216)
accumulates in the nucleus, which activates CDK1/cyclin B and
thus initiate mitosis [10].
The staining pattern of 14-3-3 isoforms in normal vulvar tissues
differs from that in vulvar carcinomas. The regulation of the
distribution of each 14-3-3 isoform during tumorigenesis and
tumor progression remains unclear however. Previously, intracel-
lular trafficking of 14-3-3 via its nuclear export signal (NES), a
leucine-rich region within the COOH-terminal, has been reported
to shuttle 14-3-3 proteins in and out of the nucleus [9,34].
However, there is no consensus in the current literature regarding
the function of this region. According to Brunet et al. [34] and
Gardino et al. [35], the NES of 14-3-3 is a ligand binding region
rather than a motif that functions in nuclear signaling transport.
This suggests that the binding of a ligand to the NES of 14-3-3
may regulate the subcellular trafficking of this ligand. Hence, the
specific subcellular locations of the 14-3-3 isoforms may be
independently regulated by their corresponding ligands.
In conclusion, the abnormal expression of 14-3-3b, c, e, f, g and
t in a high proportion of vulvar carcinomas and the correlations of
these levels with the clinicopathological features of these tumors
indicates that 14-3-3 isoforms may be involved in the progression of
vulvar carcinomas. Furthermore, 14-3-3b and e are independent
predictors of poor disease-specific survival in cancer patients due to
the high cytoplasmic levels of these proteins in cancer cells.
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